From the Sector

• Electromagnetically heatable nanomodified stent for the treatment of hollow organ tumours wins second place at the RWTH Innovation Award

Almost every fourth person who dies of cancer has a hollow organ tumour, for example in the bile duct or in the oesophagus. Such a tumour cannot usually be removed surgically. It is only possible to open the hollow organ for a short time using a stent, i.e. a tubeshaped prosthesis. However, the tumour grows back and penetrates the hollow organ through the stent. Ioana Slabu from the Institute of Applied Medical Technology and Benedict Bauer from the Institut für Textiltechnik of RWTH Aachen University have now developed a novel technology for the therapy of hollow organ tumours, which was awarded second place in the RWTH Innovation Award. This involves a polymerstent that contains magnetic nanoparticles. When electromagnetic fields are applied, these nanoparticles lead to a controlled heating of the stent material and thus of the tumour. Because the tumour reacts much more sensitively to heat than healthy tissue, it is destroyed and the hollow organ remains open. Thus, the stent develops a self-cleaning effect.  

Ioana Slabu of the AME explains: "Not only can we drastically reduce treatment costs, but above all we can provide relief for millions of patients worldwide.
 
A manufacturing process and proof of concept for magnetic hyperthermia are already in place. This novel technology has a very high development potential because it can also be used for tumours in other parts of the body such as the prostate, stomach, intestine or urinary bladder or for cardiovascular diseases.  

The AiF/IGF project started under the project title "ProNano" funded by BMWK. Now the approval for the follow-up project "ProNano2" has also been received. The approved project is called: "Validation of the innovation potential of heatable stents for heat-induced treatment of cavity tumours" and is funded by BMBF in course of the VIP+ program. With the Clinic for General, Visceral and Transplantation Surgery of the University Hospital Aachen and the Institute for Technology and Innovation Management at RWTH Aachen University, the consortium is enriched by clinical and economic expertise. Every year, RWTH Aachen University honours particularly innovative university projects with the Innovation Award. Professor Malte Brettel, Prorector for Business and Industry, presented the certificates to four outstanding projects as part of RWTHtransparent.

Toray Industries, Inc., announced that it has combined nanotechnology and fiber technology to create a cross-shaped polymethyl methacrylate (PMMA) nanopore fiber that efficiently adsorbs pathogenic proteins in the blood.

The company developed this fiber by employing its PMMA hollow fiber membrane spinning technology. Changing the nanopore size on the surface and inside the fiber makes it possible to control the types of protein that this material adsorbs. This could become a fundamental blood purification technology for a range of protein adsorption columns that cause diseases.

The fiber’s cross-shaped cross section has a larger surface area than fibers with round ones. This provides much better contact between the blood and fiber and significantly enhances protein adsorption efficiency.

Toray is the only company to have commercialized a PMMA hollow-fiber membrane artificial kidney for dialysis treatment. Its new nanopore fiber benefits from PMMA’s good protein adsorption and biocompatibility. Using the structural formation of a stereocomplex from two PMMA types entangled spirally during the spinning process to form the fiber shape, Toray made it possible for the fiber itself to develop pores of several to dozens of nanometers. Depending on the pore size, large proteins cannot go inside the pores. If they are too small, they are not trapped. This enables selective adsorption of moderately sized proteins trapped in pores.

The fiber pore sizes are adjustable to the diameters of target proteins for a range of diseases. These include inflammatory proteins in sepsis, autoantibodies in autoimmune diseases, and causative proteins in chronic illnesses. Toray’s technology is thus fundamental to developing disease-causing protein adsorption columns to purify blood.

Toray’s cross-shaped cross section suppresses inter-fiber adhesion, increasing the surface area per volume and enabling highly efficient protein adsorption. For blood purification applications, higher capacity adsorption columns increase blood removal amounts from the body, which can be especially stressful for the elderly and children. The new fiber’s highly efficient protein adsorption should contribute to compact, high-performance protein adsorption columns.